IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: JERUSSI et al.

Filed: Herewith

Application No.: To be assigned

(DIV of 09/527,442, filed March 17, 2000)

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

For: DERIVATIVES OF VENLAFAXINE

AND METHODS OF PREPARING

AND USING SAME

Attorney Docket No.: 4821-531-999

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.56, enclosed is a list of forty two (42) references for the Examiner's review and consideration. These references are listed on the enclosed Form PTO-1449 entitled "List of References Cited by Applicant." These references (A01-C22) are listed in reverse-chronological or alphabetical order. Copies of these references are not enclosed as the copies were submitted in connection with U.S. Application No. 09/527,442, filed March 17, 2000, which is the parent of this application, or cited by the Examiner in the parent application. Copies will be provided, however, upon the Examiner's request.

Identification of the foregoing references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited."

Applicants respectfully request that the Examiner review the references and make them of record by completing and returning the enclosed List of References.

DC1: 359602.1

- 1 -

No fee is believed to be due for the submission of this statement since it is being made prior to a first Office Action on the merits in the above case. If any fees are required, however, please charge such fees to Pennie & Edmonds LLP's Deposit Account No. 16-1150.

Respectfully submitted,

Date

November 25, 2003

Hoon Choi (Given a limited recognition pursuant to

the paper enclosed herewith)
PENNIE & EDMONDS LLP

1667 K Street, N.W. Washington, DC 20006

(202) 496-4400

For: Anthony M. Insogna

(Reg. No. 35,203)

PENNIE & EDMONDS LLP 12750 High Bluff Drive, Suite 300

San Diego, CA 92130 (858) 314-1200

Enclosure

	ATTY DOCKET NO.	APPLICATION NO	
	4821-531-999	To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	JERUSSI et al.		
	FILING DATE	GROUP	
	November 25, 2003	To Be Assigned	
H.C. DATENTE DO	ACTIMENTES		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,788,986	08/1998	Dodman			
-	A02	5,733,566	3/31/98	Lewis			
	A03	5,674,533	10/7/97	Santus et al.			
	A04	5,639,476	6/17/97	Oshlack et al.			
· · · · · · · · · · · · · · · · · · ·	A05	5,591,767	1/7/97	Mohr et al.			
	A06	5,354,556	10/11/94	Sparks et al.			
	A07	5,120,548	6/9/92	McClelland et al.			
	A08	5,073,543	12/17/91	Marshall et al.			
	A09	5,059,595	10/22/91	Le Grazie			
	A10	4,761,501	08/1988	Husbands et al.			
	A11	4,008,719	2/22/77	Theeuwes et al.			
	A12	3,916,899	11/4/75	Theeuwes et al.			
	A13	3,845,770	11/5/74	Theeuwes et al.			
	A14	3,598,123	8/10/71	Zaffaroni			
	A15	3,536,809	10/27/70	Applezweig			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	0 112 669 A	07/1984	EPO				
B02	2 227 743 A	08/1990	Great Britain				
B03	94/00114	01/1994	WIPO				
B04	94/00047	01/1994	WIPO				
B05	0 654 264 A	05/1995	EPO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)						
C01	Application of a First-Pass Effect Model to Characterize the Pharmacokinetic Disposition of Venlafaxine After Oral Administration to Human Subjects, Taft et al., DRUG METABOLISM AND DISPOSITION, Vol. 25, No. 10, pages 1215-1218, October 1997.					
C02	Askew, A Simple Screening Procedure for Imipramine-Like Antidepressant Agents, Life Sciences No. 10, September 1963, pp. 725-730/					
C03	Castello, R.A., and Mattocks, A.M., J. Phram. Sci. 51(2):106-108 (1962)					
C04	Handbook of Pharmaceutical Excipients, 2 nd ed., Wade and Willer eds., pp. 257-259 (1994).					

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			ATTY DOCKET NO.	APPLICATION NO			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		4821-531-999	To Be Assigned				
		APPLICANT					
		JERUSSI et al.					
			FILING DATE	GROUP			
			November 25, 2003	To Be Assigned			
		OTHER REFERENCES (Including Author, Title					
	C05	Haskins et al., DMI, Wy-45,030, Wy-45,881 and Ciramadol Inhibit Locus Coeruleus Neuronal Activity, European Journal of Pharmacolog					
		115 (1985), pp. 139-146.					
	C06	Howell, S. R., et al., Xenobiotical 24(4):315-327 (1994).					
	C07	Klamerus, K.J., et al., J. Clin. Pharmacol., 32:716-724 (1992).					
(C08	Moyer et al., Subsensitivity of the Beta-Adrenergic Receptor-Linked Adenylate Cyclase System of Rat Pineal Gland Following Repeated					
		Treatment with Desmethylimipramine and Nialamide, Molecular Pharmacology, 19:187-193, 1981.					
(C09	Moyer et al., In Vivo Antidepressant Profiles of the Novel Bicyclic Compounds Wy-45,030 and Wy-45,881, Abstracts Society for					
		Neuroscience, October 1984, pg. 261. Muth, E.A., et al., <i>Drug Develop. Res.</i> , 23:191-199 (1991).					
	C10	Muth, E.A., et al., Drug Develop. Res., 23:191-199 (1991). Muth et al., Antidepressant Biochemical Profile of the Novel Bicyclic Compounds Wy-45,030, an Ethyl Cyclohexanol Derivative,					
(CII	Biochemical Pharmacology, Vol. 35, No. 24, 1986, pp. 4493-4497.					
	C12	Pento, J.T., Drugs of the Future, 13(9):839-840 (1988).					
	C13	Physicians' Desk Reference pp. 3293-3302 (53 rd ed., 1999).					
	C14	Remingtons: The Practice of The Science and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995).					
	C14	Rudaz, S., et al., <i>Chromatographia</i> , Vol. 50, No. 5/6, 369-372(1999).					
	C16	Sinclair, J., et al., Rev. Contemp. Pharmacother., 9:333-334 (1988).					
		Steiner et al., Radioimmunoassay for Cyclic Nucleotides, The Journal of Biological Chemistry, Vol. 247, No. 4, February 25, 1972, pp.					
(C17	1106-1113.					
1	C18	von Moltke, L.L., et al., Biol. Psychiatry, 41:377-380 (1997).					
	C19	Wang, C. Paul, et al., Chirality, 4(2), 84-90 (1992).					
	C20	Wilen et al., Strategies in Optical Resolutions, Tetrahedron, Vol. 33, 19	977, pp. 2725 to 2736.				
	C21 Wood et al., The Rapid Preparation of Synaptosomes, Using a Vertical Rotor, Journal of Neurochemistry, Vol. 37, No. 3, September 198						
		pp. 795-797.					
(C22	Yardley., J.P., et al. J. Med. Chem. I 33:2899-2905 (1990)					
		· · · · · · · · · · · · · · · · · · ·					

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.